|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7806 News |
|
| «12...145146147148149150151152153154155156157» |
- Enrollment change: Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D) (clinicaltrials.gov) - Sep 7, 2011
P=N/A, N=12, Active, not recruiting, Sponsor: Nemours Children's Clinic
N=10 --> 12
- ||||| Davictrel (etanercept biosimilar) / Hanwha Chem
Enrollment closed, Combination therapy: Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients (clinicaltrials.gov) - Sep 6, 2011
P3, N=300, Active, not recruiting, Sponsor: Hanwha Chemical
N=10 --> 12 Not yet recruiting --> Active, not recruiting
- Trial completion: Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy (clinicaltrials.gov) - Sep 6, 2011
P=N/A, N=50, Completed, Sponsor: The Cleveland Clinic
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Trial completion: FREEDOMS II: Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 6, 2011
P3, N=1083, Completed, Sponsor: Novartis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||| Revamilast (GRC-4039) / Glenmark
New P2b trial: A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 6, 2011
P2b, N=406, Completed, Sponsor: Glenmark Pharmaceuticals Ltd. India
- ||||||| Humalog pen (insulin lispro) / Eli Lilly
Trial completion: Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use (clinicaltrials.gov) - Sep 6, 2011
P3, N=132, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Clinical: Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone (clinicaltrials.gov) - Sep 5, 2011
P2/3, N=30, Terminated, Sponsor: Neurologique Foundation, Inc.
Active, not recruiting --> Completed Recruiting --> Terminated; Study reached halfway point in approximately one year time period and was halted to analyze data.
- H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Clinical: Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone (clinicaltrials.gov) - Sep 5, 2011
P2/3, N=30, Terminated, Sponsor: Neurologique Foundation, Inc.
Recruiting --> Terminated; Study reached halfway point in approximately one year time period and was halted to analyze data. N=63 --> 30
- Trial completion: Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b (clinicaltrials.gov) - Sep 5, 2011
P2, N=28, Completed, Sponsor: University Hospital Inselspital, Berne
N=63 --> 30 Active, not recruiting --> Completed
- escitalopram / Generic mfg.
Trial completion: Escitalopram (Lexapro) for Depression MS or ALS (clinicaltrials.gov) - Sep 5, 2011
P3, N=13, Completed, Sponsor: University of South Carolina
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study (clinicaltrials.gov) - Sep 5, 2011
P=N/A, N=85, Completed, Sponsor: University at Buffalo
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
Trial completion: A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Sep 5, 2011
P3, N=35, Completed, Sponsor: Bio Products Laboratory
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
Enrollment change: A Study of LY2439821 in Rheumatoid Arthritis (clinicaltrials.gov) - Sep 5, 2011
P1, N=32, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed N=24 --> 32
- Simulect (basiliximab) / Novartis, Enbrel (etanercept) / Pfizer, Amgen, Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment change: Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes (clinicaltrials.gov) - Sep 5, 2011
P2, N=14, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=24 --> 32 N=20 --> 14
- ||||| diazoxide (ATH-012) / Neurotec Pharma, Advancell
New P2a trial: A Phase IIa Study of NT-KO-003 for Multiple Sclerosis (clinicaltrials.gov) - Sep 1, 2011
P2a, N=99, Completed, Sponsor: Neurotec Pharma
- New P2 trial, Preclinical: [18F]PBR111 and Microglial Activation in Multiple Sclerosis (clinicaltrials.gov) - Sep 1, 2011
P2, N=50, Terminated, Sponsor: GlaxoSmithKline
- Trial completion: Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis (clinicaltrials.gov) - Sep 1, 2011
P4, N=80, Completed, Sponsor: University Hospital of North Norway
N=20 --> 14 Active, not recruiting --> Completed
- | tofacitinib / Generic mfg.
IO biomarker: A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 1, 2011
P2, N=29, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial termination: A Single Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-ceramic Bearing in Primary Total Hip Replacement (clinicaltrials.gov) - Aug 31, 2011
P4, N=200, Terminated, Sponsor: DePuy International
Recruiting --> Completed Recruiting --> Terminated; Study terminated early due to business reasons
- ||| Enrollment closed: A Two Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Metal-on-Metal Bearing in Primary Total Hip Replacement (clinicaltrials.gov) - Aug 31, 2011
P4, N=163, Active, not recruiting, Sponsor: DePuy International
Recruiting --> Terminated; Study terminated early due to business reasons Recruiting --> Active, not recruiting
- Enrollment change: Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption (clinicaltrials.gov) - Aug 31, 2011
P=N/A, N=9, Completed, Sponsor: Atlanta VA Medical Center
Recruiting --> Active, not recruiting N=20 --> 9
- Enrollment change: Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome (clinicaltrials.gov) - Aug 30, 2011
P=N/A, N=28, Completed, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
N=20 --> 9 N=60 --> 28
- Trial completion: Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome (clinicaltrials.gov) - Aug 30, 2011
P=N/A, N=28, Completed, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
N=60 --> 28 Recruiting --> Completed
- ||||| Cosentyx (secukinumab) / Novartis
Biomarker, New P2 trial: A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients (clinicaltrials.gov) - Aug 29, 2011
P2, N=500, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- prednisone / Generic mfg.
Clinical: CORTAGE: Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years (clinicaltrials.gov) - Aug 28, 2011
P4, N=108, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: RPD: Reciprocating Medical Devices - a Study of a New Safety Device (clinicaltrials.gov) - Aug 28, 2011
P=N/A, N=437, Completed, Sponsor: University of New Mexico
Active, not recruiting --> Completed N=820 --> 437
- Clinical: Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 28, 2011
P=N/A, N=140, Active, not recruiting, Sponsor: Johns Hopkins University
- Trial completion: RPD: Reciprocating Medical Devices - a Study of a New Safety Device (clinicaltrials.gov) - Aug 28, 2011
P=N/A, N=437, Completed, Sponsor: University of New Mexico
N=820 --> 437 Recruiting --> Completed
- Clinical: The Impact of Continuous Glucose Monitoring Use on Sleep in Parents of Children With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Aug 25, 2011
P=N/A, N=30, Recruiting, Sponsor: Wolfson Medical Center
- ozanezumab (GSK 1223249) / GSK
New P1 trial: NOGO-A in Multiple Sclerosis FTIH (clinicaltrials.gov) - Aug 25, 2011
P1, N=3, Terminated, Sponsor: GlaxoSmithKline
- ||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: RAVE: Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis (clinicaltrials.gov) - Aug 23, 2011
P2/3, N=197, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- New P4 trial: Metal on Metal Versus Metal on Highly Crossed Linked Polyethylene Sytem (clinicaltrials.gov) - Aug 22, 2011
P4, N=41, Terminated, Sponsor: Capital District Health Authority, Canada
- || Enrollment closed, HEOR: HORA: Health Outcomes in Rheumatoid Arthritis in Greece (clinicaltrials.gov) - Aug 22, 2011
P=N/A, N=460, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
New P3 trial, Combination therapy: ELEMENT 1: A Study in Adults With Type 1 Diabetes (clinicaltrials.gov) - Aug 18, 2011
P3, N=400, Completed, Sponsor: Eli Lilly and Company
- New P1/2 trial: Closed-Loop Insulin Delivery in Children Less Than 7 Years of Age (clinicaltrials.gov) - Aug 18, 2011
P1/2, N=15, Recruiting, Sponsor: Children's Hospital Boston
- New P1 trial: A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Aug 18, 2011
P1, N=40, Recruiting, Sponsor: Brigham and Women's Hospital
- ||||| New P4 trial: Fingolimod -Response According to Coping - Evaluation (clinicaltrials.gov) - Aug 17, 2011
P4, N=189, Completed, Sponsor: Novartis Pharmaceuticals
- oxycodone controlled release / Generic mfg., lidocaine 5% / Generic mfg.
Enrollment change: Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis (clinicaltrials.gov) - Aug 16, 2011
P4, N=19, Terminated, Sponsor: University of Rochester
Recruiting --> Active, not recruiting N=60 --> 19
- | Xeljanz (tofacitinib) / Pfizer
Clinical: Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers (clinicaltrials.gov) - Aug 16, 2011
P1, N=24, Completed, Sponsor: Pfizer
N=60 --> 19 Recruiting --> Completed
- |||||||||| Betaseron (IFN-β-1b) / Bayer
New P2/3 trial: Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 15, 2011
P2/3, N=70, Completed, Sponsor: University of Turku
- LX 2931 / Lexicon Pharma
New P1 trial: A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 14, 2011
P1, N=10, Completed, Sponsor: Lexicon Pharmaceuticals
- |||| firategrast (SB683699) / GSK
Trial completion: Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 11, 2011
P2, N=343, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Completed
- Enrollment change: Study of Alternative Exercise Therapies for Progressive Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 10, 2011
P=N/A, N=10, Completed, Sponsor: Hicks, Audrey, Ph.D.
Recruiting --> Completed N=20 --> 10
- |||||||||| Tysabri (natalizumab) / Biogen, Royalty
New P3 trial: ASCEND: A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Aug 10, 2011
P3, N=856, Active, not recruiting, Sponsor: Biogen Idec
- New P2 trial: REUMAP: Bovine Intestinal Alkaline Phosphatase (bIAP) Modulating Rheumatoid Arthritis (clinicaltrials.gov) - Aug 10, 2011
P2, N=10, Recruiting, Sponsor: Alloksys Life Sciences B.V.
- Trial completion: Study of Alternative Exercise Therapies for Progressive Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 10, 2011
P=N/A, N=10, Completed, Sponsor: Hicks, Audrey, Ph.D.
N=20 --> 10 Recruiting --> Completed
- Trial completion: Improving Gait in Multiple Sclerosis (MS) - Strength Training or Treadmill Walking? (clinicaltrials.gov) - Aug 10, 2011
P=N/A, N=28, Completed, Sponsor: St. Olavs Hospital
Recruiting --> Completed Recruiting --> Completed
- | GSK 2018682 / GSK
New P1 trial: Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers (clinicaltrials.gov) - Aug 10, 2011
P1, N=40, Completed, Sponsor: GlaxoSmithKline
- |||| decernotinib (VX-509) / Vertex
Trial completion: A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 10, 2011
P2, N=206, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| ISIS 353512 / Ionis
New P2 trial: Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis (clinicaltrials.gov) - Aug 9, 2011
P2, N=51, Completed, Sponsor: Isis Pharmaceuticals